PT-141 (Bremelanotide) HSA/FSA Eligibility and Submission: Complete 2026 Guide

What Is PT-141 (Bremelanotide) and Why Does the Distinction Matter for HSA/FSA?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, under the brand name Vyleesi, manufactured by Palatin Technologies. [1] It is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) characterized by low sexual desire causing marked distress. [1] The clinical name "PT-141" originates from Palatin's peptide-trial numbering and refers to the same active molecule.

The HSA/FSA question turns on one core IRS rule: expenses that treat a diagnosed condition are medical expenses; expenses that improve general health or wellness are not. [2] Vyleesi treats a specific DSM-5-recognized disorder, which puts it firmly in the "medical" column.

FDA Approval and Its Reimbursement Significance

FDA approval is not a legal requirement for HSA/FSA eligibility, but it removes the largest administrative barrier. [2] Plan administrators rarely challenge reimbursements for FDA-approved drugs dispensed by a licensed pharmacy with a valid prescription. Compounded PT-141, which is not FDA-approved as a finished product, requires additional documentation to clear the same hurdle.

The FDA's approval was based on two key Phase 3 trials. In RECONNECT Study 1 (N=394), the proportion of satisfying sexual events per month increased by a mean of 0.7 versus 0.4 for placebo (P<0.001), and the Female Sexual Function Index desire domain score improved significantly. [3] Regulatory approval signals to payers that the drug has established clinical evidence, which strengthens your reimbursement argument.

HSDD as a Recognized Diagnosis

HSDD is classified in DSM-5 as Female Sexual Interest/Arousal Disorder. [4] The American College of Obstetricians and Gynecologists affirms that HSDD is a medical condition warranting pharmacologic treatment when distress is present and psychosocial causes have been excluded. [5] Having an ICD-10 code on your prescription or Letter of Medical Necessity (F52.0 for HSDD) strengthens your claim considerably.

IRS Rules That Govern HSA and FSA Reimbursement

IRS Publication 502 defines a qualifying medical expense as one that "diagnoses, cures, mitigates, treats, or prevents disease." [2] Prescription drugs dispensed by a licensed pharmacist meet this definition automatically when a physician has determined they are medically necessary. [2] No separate IRS ruling covers bremelanotide specifically, but the general prescription-drug rule applies cleanly.

The "Prescribed" Requirement

A prescription written by a licensed U.S. Physician, nurse practitioner, or physician assistant satisfies the IRS "prescribed" requirement for HSA/FSA purposes. [2] Telehealth prescriptions carry equal legal weight as in-person prescriptions under DEA and state pharmacy board rules, provided the prescriber holds a valid license in the patient's state. [6] Most HSA/FSA administrators accept telehealth prescriptions without additional documentation for FDA-approved drugs.

Letter of Medical Necessity for Compounded PT-141

Compounded peptides are not FDA-approved finished drug products. [7] For compounded PT-141, plan administrators may request a Letter of Medical Necessity (LMN) from your prescriber. The LMN should:

• State the ICD-10 diagnosis code (F52.0 or N94.8 as applicable)
• Explain why the compounded formulation is medically appropriate
• Specify the dose, dosing frequency, and expected treatment duration
• Be signed and dated by the prescribing clinician

The IRS does not mandate a specific LMN format, but the document should include enough clinical detail that a claims reviewer can confirm the expense is medical rather than cosmetic. [2]

Dependent and Spouse Coverage

HSA funds can reimburse qualified medical expenses for the account holder, the account holder's spouse, and any dependent claimed on a federal tax return. [2] An FSA covers the same group. If bremelanotide is prescribed to a spouse or qualifying dependent, the same documentation rules apply.

Step-by-Step Submission Process

Submitting a bremelanotide claim takes four steps regardless of whether you use a health FSA through an employer, a dependent-care FSA, or a self-directed HSA.

Step 1, Obtain Itemized Pharmacy Documentation

Request an itemized receipt or Explanation of Benefits from your pharmacy. The document must show:

• Patient name
• Date of service
• Drug name (bremelanotide or Vyleesi)
• NDC (National Drug Code) number
• Quantity dispensed
• Total amount charged

Retail pharmacies generate this automatically. Compounding pharmacies occasionally need a direct request; ask at the time of pickup or order.

Step 2, Confirm Your Plan's Eligibility List

Most major HSA/FSA administrators (HealthEquity, Optum Bank, WEX Health, FSAStore, Benefit Resource) publish an online eligibility lookup tool. [8] Enter "bremelanotide" or the NDC number. FDA-approved drugs dispensed by prescription almost always appear as automatically eligible. If the lookup returns "requires LMN," proceed to Step 3. If the lookup returns "ineligible," contact your plan administrator directly before assuming the drug is excluded, database errors occur.

Step 3, Gather Supporting Documentation if Required

For compounded PT-141 or if the administrator flags the claim, collect:

1. A copy of the prescription
2. Your Letter of Medical Necessity (see section above)
3. The itemized pharmacy receipt

Keep digital copies. IRS rules require you to retain documentation for three years after filing the return for the year in which the expense occurred. [2]

Step 4, Submit the Claim

Log in to your HSA or FSA portal and upload the documents. Most administrators process standard drug claims in 5 to 15 business days. Some HealthEquity and Optum accounts offer real-time debit-card processing at the pharmacy; in that case, no post-purchase submission is needed because the card captures the transaction automatically.

If a claim is denied, request the denial reason in writing. Common denial reasons and resolutions:

• "Not prescribed", submit a copy of the prescription
• "Cosmetic or enhancement", submit the LMN with ICD-10 diagnosis
• "Not an eligible expense", cite IRS Publication 502 Section on Prescription Drugs in your appeal letter [2]

How to Get PT-141 (Bremelanotide) Cheaper

Bremelanotide's list price creates a real access problem. A single auto-injector of Vyleesi carries a retail price near $950, $1,200. [9] Multiple strategies can reduce that meaningfully.

Palatin / Vyleesi Manufacturer Savings Card

Palatin Technologies offers a co-pay savings card through the Vyleesi website for commercially insured patients. Eligible patients may pay as little as $0 per fill, though the program excludes patients covered by Medicare, Medicaid, or any federal healthcare program. [9] Card terms change; verify current terms at the manufacturer's site before prescribing or dispensing.

GoodRx and Pharmacy Discount Programs

GoodRx, RxSaver, and NeedyMeds list discount coupons that can reduce out-of-pocket costs at retail pharmacies. These discounts cannot be combined with insurance on the same transaction, but they can be used when paying cash and then submitting for HSA/FSA reimbursement. [10] Compare the discounted cash price against your insurance co-pay before deciding which route saves more.

Compounding Pharmacy Pricing

Licensed 503A compounding pharmacies formulate bremelanotide as a subcutaneous injection or intranasal spray at lower unit costs than the branded auto-injector. [7] Prices vary by pharmacy and formulation but frequently range from $80, $200 per vial at telehealth-affiliated compounders. Because compounded PT-141 is not FDA-approved, the FDA and pharmacists advise confirming the pharmacy holds state licensure and PCAB accreditation before purchasing. [7]

The table below summarizes the main cost pathways for bremelanotide in 2026.

| Pathway | Estimated Cost per Cycle | HSA/FSA Eligible | Notes | |---|---|---|---| | Vyleesi retail, no insurance | $950, $1,200 | Yes, with Rx | Single auto-injector | | Vyleesi + manufacturer card | $0, $99 | Yes, for remaining cost | Commercial insurance only | | Vyleesi + insurance co-pay | $30, $150 | Yes, for co-pay portion | Plan-dependent | | GoodRx cash at retail pharmacy | $400, $700 | Yes, with Rx | Estimate; verify current price | | Compounded PT-141 (503A) | $80, $200 per vial | Yes, with Rx + LMN | Not FDA-approved |

Telehealth Prescription Access

Obtaining a prescription through a telehealth platform typically costs $75, $150 per visit, and many platforms include the consultation in a monthly membership. [6] The visit fee itself is HSA/FSA eligible as a medical expense. [2] Telehealth access removes the need for an in-person specialist referral, which can delay care by four to six weeks in areas with limited sexual-medicine specialists.

Insurance Coverage for Vyleesi

Most commercial insurers cover Vyleesi with prior authorization. The prior authorization process typically requires:

• A documented HSDD diagnosis with at least 6 months of symptom duration
• Confirmation that distress is present and attributable to HSDD rather than relationship or psychiatric factors
• Absence of contraindications (notably, cardiovascular disease, moderate-to-severe hepatic impairment)

The FDA's prescribing information notes that nausea occurs in approximately 40% of Vyleesi users and that the drug is contraindicated with naltrexone use due to pharmacokinetic interaction. [1] Including these considerations in prior authorization documentation demonstrates clinical thoroughness and speeds approval.

Medicare and Medicaid Coverage

Medicare Part D coverage of Vyleesi depends on the individual plan's formulary. As of 2026, many Part D plans do not include Vyleesi on their formulary, making HSA reimbursement relevant only for beneficiaries who also hold an HSA from a prior high-deductible health plan. [11] Medicaid coverage varies by state; contact your state Medicaid office directly.

Patients who are Medicare beneficiaries cannot contribute to an HSA while enrolled in Medicare, but they can spend down balances accumulated before enrollment. [11] Those accumulated funds can reimburse bremelanotide costs if documentation is complete.

Clinical Evidence Supporting Medical Necessity Documentation

A strong Letter of Medical Necessity rests on published clinical evidence. Having this evidence available when communicating with insurance reviewers or FSA administrators can resolve disputes faster.

Phase 3 Trial Data

The two key RECONNECT trials enrolled 1,267 premenopausal women with HSDD across Study 1 (N=394) and Study 2 (N=399, plus a pooled analysis). [3] Both trials used the Patient-Reported Outcomes Measurement Information System (PROMIS) desire domain and the Female Sexual Distress Scale-Revised (FSDS-R) as co-primary endpoints. Bremelanotide produced statistically significant improvements on both instruments versus placebo (P<0.001). [3] This strong trial record distinguishes bremelanotide from many compounded peptides that lack Phase 3 data.

Regulatory Basis

The FDA's approval letter and prescribing information are publicly accessible via the FDA's drug database. [1] Citing the specific NDA number (NDA 210557) in correspondence with insurance reviewers provides an unambiguous reference point. [1]

Endocrine Society and ACOG Guidance

The Endocrine Society's clinical practice guideline on female sexual dysfunction states that pharmacologic treatment is appropriate for HSDD when psychological and relationship contributors have been addressed. [12] The American College of Obstetricians and Gynecologists similarly supports pharmacologic options for HSDD in appropriately selected patients. [5] Quoting these guidelines in your LMN can preempt the "cosmetic or enhancement" denial argument.

The Endocrine Society guideline states: "We recommend that clinicians discuss the benefits and risks of pharmacological treatments, including flibanserin and bremelanotide, with women who have HSDD and who have not responded to or who are not candidates for non-pharmacological approaches." [12]

Common Questions About Documentation and Eligibility

What If My HSA/FSA Administrator Denies the Claim?

File a formal appeal within the deadline printed on the denial notice (usually 30 to 60 days). Include IRS Publication 502's prescription-drug section, a copy of your prescription, and, if applicable, the LMN. [2] If the appeal is denied a second time, you can escalate to the Department of Labor if the FSA is employer-sponsored, or request an IRS private letter ruling, though the latter is rarely cost-effective for a single drug claim.

Can I Use HSA/FSA for the Prescriber Visit?

Yes. A visit to a licensed physician, nurse practitioner, or telehealth provider to diagnose and manage HSDD qualifies as a medical expense under IRS Publication 502 independently of whether a drug is ultimately prescribed. [2]

Does the IRS Distinguish Between Branded and Compounded Versions?

The IRS distinguishes by whether a substance is a "medicine or drug" requiring a prescription, not by FDA approval status. [2] A valid prescription from a licensed U.S. Practitioner applied to compounded bremelanotide satisfies that requirement. The administrative challenge is practical, not legal: plan administrators may apply stricter internal policies than IRS rules technically require, which is why the LMN adds an important layer of documentation.

Special Situations

Prior-Year Expenses and HRA Reimbursement

If you incurred bremelanotide costs in a prior tax year and did not submit them, you may still be able to seek reimbursement from an HSA (no deadline for HSA reimbursement as long as the expense occurred after the HSA was established and the documentation exists). [2] Health Reimbursement Arrangements (HRAs) are employer-controlled and have plan-specific deadlines; check your Summary Plan Description.

Limited-Purpose FSAs

A limited-purpose FSA restricts reimbursement to dental and vision expenses while you are enrolled in a high-deductible health plan alongside an HSA. Bremelanotide does not qualify under a limited-purpose FSA until you have met your medical deductible and the FSA converts to general-purpose status. [2]

Dependent Care FSAs

Dependent-care FSAs cover childcare and elder-care costs only. They cannot reimburse any prescription drug, including bremelanotide. [2]